Sp108

REDUCING READMISSIONS FOR GI BLEEDING

Date
May 6, 2023
Explore related products in the following collection:

Society: AGA

This session is designed to demonstrate successful quality improvement in practices and across institutions with the focus on and meaningful real world implementation across a range of GI conditions. This session will discuss how to translate clinical research into quality improvement initiatives leading to successful improvement in patient outcomes. Attendees will also be able to incorporate feedback to improve patient satisfaction as well as reimbursement strategies as well as improving healthcare for socially disadvantaged populations and women's health.

Presenter

Speaker Image for Shazia Siddique
University of Pennsylvania

Tracks

Related Products

Thumbnail for PLACEHOLDER
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
Thumbnail for PLACEHOLDER
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for PANEL DISCUSSION
PANEL DISCUSSION
This session will provide attendees with an overview of physician advocacy, how it impacts the GI community and how to get involved…
Thumbnail for Q&A
Q&A
This session is designed to demonstrate successful quality improvement in practices and across institutions with the focus on and meaningful real world implementation across a range of GI conditions…